@article{J Samuelsson_M Mutschler_G Birgegard_P Gram-Hansen_M Bjorkholm_HL Pahl_2006, place={Pavia, Italy}, title={Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia}, volume={91}, url={https://haematologica.org/article/view/4163}, DOI={10.3324/%x}, abstractNote={Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.}, number={9}, journal={Haematologica}, author={J Samuelsson and M Mutschler and G Birgegard and P Gram-Hansen and M Bjorkholm and HL Pahl}, year={2006}, month={Sep.}, pages={1281-1282} }